Acro Biomedical Co., Ltd.
ACBM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $659 | $1,198 |
| % Growth | – | -100% | -45% | – |
| Cost of Goods Sold | $0 | $0 | $518 | $938 |
| Gross Profit | $0 | $0 | $141 | $260 |
| % Margin | – | – | 21.3% | 21.7% |
| R&D Expenses | $0 | $4,795 | $10,080 | $5,285 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $38 | $3,998 | $5,930 | $2,668 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $12 | $0 | $0 |
| Operating Expenses | $38 | $8,804 | $16,010 | $7,953 |
| Operating Income | -$38 | -$8,804 | -$15,870 | -$7,694 |
| % Margin | – | – | -2,410% | -642.5% |
| Other Income/Exp. Net | -$4 | -$3 | -$2 | -$4 |
| Pre-Tax Income | -$42 | -$8,808 | -$15,871 | -$7,698 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$42 | -$8,808 | -$15,871 | -$7,702 |
| % Margin | – | – | -2,410.2% | -643.2% |
| EPS | -0.001 | -0.15 | -0.26 | -0.14 |
| % Growth | 99.5% | 42.3% | -85.7% | – |
| EPS Diluted | -0.001 | -0.15 | -0.26 | -0.14 |
| Weighted Avg Shares Out | 60,042 | 60,042 | 60,042 | 53,839 |
| Weighted Avg Shares Out Dil | 60,042 | 60,042 | 60,042 | 53,839 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4 | $3 | $2 | $4 |
| Depreciation & Amortization | $0 | $8,792 | $0 | $7,694 |
| EBITDA | -$38 | $0 | -$15,870 | $0 |
| % Margin | – | – | -2,410% | 0% |